Αρχική World News Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer

Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer

In BRCA1/2-mutated, HER2-negative advanced breast cancer, talazoparib did not significantly improve overall survival (OS) versus chemotherapy according to final OS analysis of the EMBRACA trial. The OS was generally consistent across subgroups including by prior platinum, hormone-receptor status, or line of treatment. Most patients received subsequent systemic treatments, which may have confounded the OS outcome. Toxicities were managed by supportive care medication/dose modifications. Safety was consistent with previous observations. Extended follow-up of patient reported outcomes (PROs) continued to favour talazoparib over chemotherapy. The findings are reported by Dr Jennifer K. Litton of the Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center in Houston, TX, USA and colleagues on 20 August 2020 in the Annals of Oncology.

The authors reported in the study background that previously reported results from this study showed that talazoparib prolong progression-free survival in comparison to chemotherapy (hazard ratio [HR] 0.542, 95% confidence interval [CI] 0.413–0.711; p < 0.0001) and improve PROs in patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer.

In total 431 patients were randomised in this study, 287 patients to talazoparib and 144 patients to chemotherapy. From randomised patients, 412 patients have been treated; 286 patients received talazoparib and 126 patients received chemotherapy.

Until 30 September 2019, 216 deaths (75.3%) occurred in talazoparib group and 108 deaths (75.0%) occurred in chemotherapy group. Median follow-up was 44.9 and 36.8 months, respectively. The HR for OS with talazoparib versus chemotherapy was 0.848 (95% CI 0.670–1.073; p = 0.17). Median OS was 19.3 months in talazoparib group and 19.5 months in chemotherapy group. Kaplan-Meier survival percentages for talazoparib versus chemotherapy were 71% and 74% at month 12, 42% and 38% at month 24, and 27% and 21% at month 36.

Most patients received subsequent treatments in both groups, with 46.3% of patients in talazoparib group and 41.7% in chemotherapy group who received platinum, while 4.5% patients in talazoparib group and 32.6% in chemotherapy group received a poly(ADP-ribose) polymerase (PARP) inhibitor. By adjusting for subsequent PARP and/or platinum use, HR for OS was 0.756 (95% bootstrap CI 0.503–1.029).

Grade 3 and 4 adverse events occurred in 69.6% patients who received talazoparib and 64.3% patients who received chemotherapy, which is consistent with previous reports. Extended follow-up showed significant overall improvement and delay in time to definitive clinically meaningful deterioration in global health status/quality of life and breast symptoms favouring talazoparib versus chemotherapy (p < 0.01 for all), which is consistent with initial analyses.

The authors concluded that in germline BRCA1/2-mutated, HER2-negative advanced breast cancer, talazoparib did not significantly improve OS over chemotherapy. However, subsequent treatments may have impacted the analysis. Safety was consistent with previous observations. The PROs continued to favour treatment with talazoparib.

This work was sponsored by Medivation, which was acquired by Pfizer Inc. in September 2016.


Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology; Published online 20 August 2020. DOI: https://doi.org/10.1016/j.annonc.2020.08.2098



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women Under 40

U.S. breast cancer death rates decreased by about 1% per year between 2013 and 2018. What were the new case rates during that same...

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

A large, observational, registry-based study that leveraged systematically collected data gathered both retrospectively and prospectively through the International Replication Repair Deficiency Consortium reveals impressive...

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...